ARROWHEAD PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-25.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2025-11-25
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2013-12-31 was 0.00%.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-09-30 | 0.00% 10-K · filed 2025-11-25 | |||
| 2024-09-30 | 0.00% 10-K · filed 2025-11-25 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-08 | |||
| 2023-09-30 | 0.00% 10-K · filed 2025-11-25 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2023-05-02 | |||
| 2022-09-30 | 0.00% 10-K · filed 2024-11-26 | |||
| 2021-09-30 | 0.00% 10-K · filed 2023-11-29 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-04 | |||
| 2020-09-30 | 0.00% 10-K · filed 2022-11-28 | |||
| 2014-09-30 | 0.00% 10-K · filed 2014-11-25 | |||
| 2014-06-30 | 0.00% 10-Q · filed 2014-08-12 | |||
| 2014-03-31 | 0.00% 10-Q · filed 2014-05-06 | |||
| 2013-12-31 | 0.00% 10-Q · filed 2014-02-04 | |||
| 2013-09-30 | 0.00% 10-K · filed 2014-11-25 | |||
| 2013-06-30 | 0.00% 10-Q · filed 2014-08-12 | |||
| 2013-03-31 | 0.00% 10-Q · filed 2014-05-06 | |||
| 2012-09-30 | 0.00% 10-K · filed 2014-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |